No abstract

CVS and 10 (1.3%) had an amniocentesis even after a normal 1T/2T screen. Of the 273 mothers who had ''high risk'' on the cFT screen with a normal fetal scan, 117 (42.8%) had amniocentesis, 91 (33.3%) had cfDNA and 65 (23.8%) underwent CVS. Of the 229 mothers who had a ''high risk'' result on the STS with normal fetal scan, 207 (90.3%) had amniocentesis and 22 (9.6%) had cfDNA testing. 5/248 mothers (2.1%) who had cfDNA testing, reported as ''high risk'', underwent invasive testing. Aneuploidy was confirmed in 3 fetuses, there were 2 (40%) false-positive results for T21. 2 more out of 248 (0.8%) mothers with no results had a normal karyotype confirmed on amniocentesis. Conclusions: In the absence of ''increased risk'' based on 1T or 2T trimester screen, mothers are more likely to choose non-invasive testing, especially when above the age of 35 years. However, in presence of a ''high risk'' result on cFT or 2T screen, the majority chose to undergo invasive testing. With a ''high/ no'' result on cfDNA testing, confirmatory test preferably, amniocentesis is mandatory. VP29.06 Cell-free DNA screening for fetal aneuploidy by targeted method based on microarray quantitation as primary test in the average risk population: results from a single European laboratory

No abstract